4.7 Review

Acute Heart Failure Syndromes

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 53, Issue 7, Pages 557-573

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2008.10.041

Keywords

heart; failure; decompensated; acute; syndromes

Funding

  1. Abbott
  2. Astellas
  3. Bayer
  4. AstraZeneca
  5. Corthera
  6. Debiopharm
  7. Errekappa Terapeutici
  8. EKR Therapeutics
  9. GlaxoSmithKline
  10. Johnson Johnson
  11. Medtronic
  12. Merck
  13. Nile
  14. Novartis
  15. Otsuka
  16. PeriCor
  17. PDL BioPharma
  18. Scios Inc
  19. Solvay Pharmaceuticals
  20. Sigma-Tau
  21. Biogen Idec
  22. Palatin Technologies

Ask authors/readers for more resources

Heart failure resulting in hospitalization represents a significant and growing health care burden. Heterogeneity characterizes this group in terms of mode of presentation, pathophysiology, and prognosis. The vast majority of patients symptomatically improve during hospitalization; however, their early post-discharge rehospitalization and mortality rates continue to be high. Worsening signs and symptoms, neurohormonal, and renal abnormalities occurring soon after discharge may contribute to these high post-discharge event rates. Currently available assessment modalities combined with recent advances in cardiovascular therapies provide present-day opportunities to improve post-discharge outcomes. Further investigation into pathophysiologic targets and novel approaches to clinical trial design are needed. Improving post-discharge outcomes is the single most important goal in the management of acute heart failure syndromes. (J Am Coll Cardiol 2009; 53: 557-73) (C) 2009 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available